Abstract:Introduction Most clinical studies have demonstrated that low-intensity extracorporeal shockwave therapy (Li-ESWT) can improved erectile function in patients with erectile dysfunction (ED). The EAU guideline recommended to use Li-ESWT for mild vasculogenic ED patients. However, the therapeutic advantages of Li-ESWT combined with phosphodiesterase type 5 inhibitors (PDE5i) have not been explored clearly in clinical practice for mild and moderate ED patients. Objective To compare the therapeutic effects of Li-ESWT and Li-ESWT combined with PDE5i in mild and moderate ED patients with 8≤IIEF-5≤16 from a multicenter clinical study in China. Methods Patients with ED which IIEF-5 score is less than 22 and aged 18–60 years old were enrolled from three clinical centers from Jun. 2019 to Mar. 2023. The demographic data, International Index of Erectile Function-5 (IIEF-5), erectile hardness score (EHS) and self-reported symptom questions were collected. Patients were treated by a linear low-energy shock waves generator (Renova). Low-intensity shock wave (energy density of 0.09mJ/mm2) treatments were applied (once a week, 4 weeks in total, 5000 shocks each time). Patients in Li-ESWT combined with PDE5i group took 5mg of tadalafil once a day for one continuous month during ESWT. Comparative analyses of pre- and post-treatment and intergroup were used for statistics. Results In total, 42 ED cases (37.43±11.86 years) in Li-ESWT group and 116 cases (37.41±10.14 years) in combined group were enrolled for analysis. The IIEF-5 score and EHS in both groups were significantly improved after 1 month treatment (p<0.01). Compared with Li-ESWT group, patients in combined group significantly had higher self-reported efficiency (61.2% vs. 47.6%, p=0.013), IIEF-5 scores (15.34±7.15 vs. 13.96±7.71, p=0.039) and EHS (2.85±0.82 vs. 2.69±0.89, p=0.050). In the mild and moderate ED (with 8≤IIEF-5≤16) sub-group, 30 ED cases (36.81±10.99 years) in Li-ESWT group and 96 cases (36.80±10.69 years) in combined group were enrolled for analysis. The combined regimen showed better therapeutic advantages, including effective parameters IIEF-5(14.50±6.74 vs. 12.87±8.54, p=0.040), EHS (2.85±0.75 vs. 2.81±0.67, p=0.046) and self-reported efficiency (64.2% vs. 54.1%, p=0.001). Conclusions Li-ESWT can effectively improve erectile function in this multicenter clinical study in China, and the combination of Li-ESWT with daily use PDE5i had a better therapeutic effect on Chinese ED patients, especially on mild and moderate ED. Long-term follow-up with large sample study need to be developed for exploring the optimal therapeutic regimen. Disclosure No.

[Safety and efficacy of L-carnitine and tadalafil for late-onset hypogonadism with ED: a randomized controlled multicenter clinical trial].

Tadalafil Improves Total Testosterone, IIEF Score and SEP in Old and Middle-Aged Males with Late-Onset Hypogonadism

[A Controlled Randomized Trial of the Use of Combined L-carnitine and Acetyl-L-carnitine Treatment in Men with Oligoasthenozoospermia].

[Low-Dose Tadalafil Combined with Shuganyiyang Capsules for Mild-to-moderate Erectile Dysfunction].

Chinese herbal medicine combined with tadalafil for erectile dysfunction: a systematic review and meta-analysis

Long-term tadalafil once daily in Chinese men with erectile dysfunction: a 2-year final analysis of a post-marketing, multicenter, randomized, open-label trial

The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study

Efficacy and Safety of On‐demand Tadalafil for the Treatment of Erectile Dysfunction in South‐East Asian Men

Efficacy And Safety Of Tadalafil 5 Mg Once-Daily In Asian Men With Both Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia And Erectile Dysfunction: A Phase 3, Randomized, Double-Blind, Parallel, Placebo- And Tamsulosin-Controlled Study

Efficacy and Safety of Aildenafil Citrate in Chinese Men with Erectile Dysfunction: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial

The Effect of the Combination of Ginseng, Tribulus Terrestris, and L-arginine on the Sexual Performance of Men with Erectile Dysfunction: a randomized, double-blind, parallel, and placebo-controlled clinical trial

An Open, Comparative, Multicentre Clinical Study of Combined Oral Therapy with Sildenafil and Doxazosin GITS for Treating Chinese Patients with Erectile Dysfunction and Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

The Prevalence of Erectile Dysfunction among Subjects with Late-Onset Hypogonadism: a Population-Based Study in China.

Evaluation of the long-term safety and effectiveness of tadalafil once daily in Chinese men with erectile dysfunction: interim results of a multicenter, randomized, open-label trial

An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate

65-Month Testosterone Replacement Therapy for Androgen Deficiency-Induced ED:A Case Report and Review of the Literature

(281) Low-Intensity Shockwave Therapy Combined with Tadalafil 5mg Daily has Better Efficacy for Mild and Moderate Erectile Dysfunction: The Preliminary Results of a Multicenter Clinical Study in China

Double‐blind, randomised, placebo‐controlled trial on the effect of L‐carnitine and L‐acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia

Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses

P-01-003 Investigation of Prevalence Status of Erectile Dysfunction Based the Subjects of Late-Onset Hypogonadism in a Chinese Community Population

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late‐onset hypogonadism